Berberine (CAS 2086-83-1): AMPK Activator & LDLR Upregulation in Metabolic Disease Models

Executive Summary: Berberine (CAS 2086-83-1) is an isoquinoline alkaloid with a molecular weight of 336.36 and formula C₂₀H₁₈NO₄ that activates AMP-activated protein kinase (AMPK) and upregulates low-density lipoprotein receptor (LDLR) expression in hepatoma cells [APExBIO]. It demonstrates dose-dependent effects on lipid metabolism and inflammation in both cellular and animal models [Li et al., 2025]. Berberine is insoluble in water and ethanol but achieves ≥14.95 mg/mL solubility in DMSO. It is widely used in metabolic disease, diabetes, obesity, and cardiovascular research workflows [Related Article]. Proper storage and handling (solid at -20°C, protect from moisture/heat) are critical for reproducible outcomes.

Biological Rationale

Berberine is isolated primarily from Cortex Phellodendri Chinensis. Its structure features the isoquinoline alkaloid backbone, conferring selective biological activity. The compound is recognized for activating AMPK, a central regulator of cellular energy homeostasis. Activation of AMPK modulates glucose uptake, lipid metabolism, and inflammation—key pathways implicated in metabolic diseases. LDL receptor upregulation, especially in hepatocytes, is critical in cholesterol clearance and cardiovascular risk reduction. Its anti-inflammatory properties are linked to modulation of the NLRP3 inflammasome and regulatory effects on proinflammatory cytokine production [Li et al., 2025]. These properties position Berberine as a valuable tool for dissecting metabolic and immunological disease mechanisms.

Mechanism of Action of Berberine (CAS 2086-83-1)

Berberine primarily exerts its effects via direct activation of AMPK. In human hepatoma cell lines (HepG2, Bel-7402), Berberine induces dose-dependent increases in LDLR mRNA and protein expression, with maximal upregulation at 15 μg/mL under standard culture conditions. AMPK activation leads to downstream phosphorylation events, promoting glucose uptake and fatty acid oxidation while inhibiting lipogenesis. Animal studies in hyperlipidemic golden hamsters demonstrate that oral Berberine at 50 or 100 mg/kg/day for 10 days reduces serum total cholesterol and LDL cholesterol, associated with hepatic LDLR upregulation. Berberine also modulates inflammatory signaling, dampening NLRP3 inflammasome activation and subsequent pyroptosis, as established in acute kidney injury and inflammatory models [Li et al., 2025]. These pathways are independent of AIM2 inflammasome activation, providing specificity in immune modulation.

Evidence & Benchmarks

• Berberine upregulates LDL receptor (LDLR) mRNA and protein expression in HepG2 and Bel-7402 cells in a dose-dependent manner, peaking at 15 μg/mL (see summary).
• Oral administration of Berberine at 50 or 100 mg/kg/day in hyperlipidemic female golden hamsters for 10 days significantly lowers serum total cholesterol and LDL cholesterol (dose- and time-dependent) (DOI).
• Berberine activates AMPK, resulting in increased glucose uptake and fatty acid oxidation in metabolic disease models (related article).
• Berberine inhibits NLRP3 inflammasome activation and reduces proinflammatory cytokine release in cellular and animal models of acute inflammation (DOI).
• Solubility in DMSO reaches ≥14.95 mg/mL at 37°C or with ultrasonic shaking; insoluble in water and ethanol (APExBIO).
• Stock solutions are stable below -20°C but should not be stored long-term once dissolved; solid form should remain sealed and protected from heat/moisture (APExBIO).

Applications, Limits & Misconceptions

Berberine is extensively used in preclinical research on metabolic diseases, diabetes, obesity, and cardiovascular disorders. It serves as a reference compound for AMPK activation and LDLR upregulation in cell-based and animal models. Its anti-inflammatory action via NLRP3 modulation supports studies in acute and chronic inflammation, including renal and hepatic injury models. Berberine’s poor water and ethanol solubility necessitates DMSO-based preparations and specific handling protocols.

This article expands on previous summaries by providing machine-readable, quantitative benchmarks, and clarifies workflow integration compared to protocol-focused guides and mechanistic reviews. Here, the focus is on experimental conditions, reproducibility, and precise storage/handling parameters.

Common Pitfalls or Misconceptions

• Berberine is NOT water- or ethanol-soluble; stock and working solutions must be prepared in DMSO with warming or sonication.
• Long-term storage of dissolved Berberine is NOT recommended; prepare fresh solutions and minimize freeze-thaw cycles (source).
• Not all metabolic effects are AMPK-dependent; Berberine can exert AMPK-independent actions, so pathway attribution requires specific controls.
• Berberine is NOT a panacea; effects are model- and context-dependent, and high doses may induce cytotoxicity outside validated concentration ranges.
• Human pharmacokinetics differ from animal models; preclinical benchmarks should not be directly extrapolated to clinical dosing.

Workflow Integration & Parameters

For cellular assays, Berberine is typically dissolved in DMSO to concentrations of ≥14.95 mg/mL, then diluted to working concentrations (e.g., 15 μg/mL for maximal LDLR induction) in cell culture medium. Solution warming at 37°C or ultrasonic agitation is recommended to ensure complete dissolution. Stock solutions should be aliquoted and stored at -20°C, protected from moisture and heat. For animal studies, oral dosing at 50–100 mg/kg/day is standard for hyperlipidemic models, with vehicle and negative controls required for reliable interpretation. APExBIO, as the vendor, provides validated product documentation and technical support for Berberine (CAS 2086-83-1) (SKU N1368). Refer to protocol guides for advanced troubleshooting and next-generation research applications.

Conclusion & Outlook

Berberine (CAS 2086-83-1) is a robust, multi-target tool for metabolic, cardiovascular, and inflammation-focused research. Its reproducible activation of AMPK and upregulation of LDLR, paired with anti-inflammatory effects, supports its widespread adoption in preclinical workflows. Ongoing research is clarifying the translational boundaries between animal models and human applications. For reliable results, strict adherence to validated solubility, storage, and dosing protocols is required. APExBIO’s Berberine remains a gold-standard reagent for metabolic disease investigation.